drug · small molecule
avenciguat
Phase 2updated 3mo agoby Boehringer Ingelheim International GmbH🔗 ChEMBL
Phase 2community read0 votes
Small molecule drug with a maximum clinical stage of Phase 2 (across all indications), with 4 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying avenciguat
- phase2A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
- phase2A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
- phase2A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
- phase1A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems
- phase2A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly
- phase2A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease
- phase1A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood
News(0)
no news has mentioned this drug yet
Data sources
last refreshed just now
Found something off?
comments(0)
5-min edit window · permanent after that